A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 04 Sep 2017
At a glance
- Drugs ABBV 553 (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors AbbVie
- 04 Sep 2017 According to an Inventiva Pharma media release, Abbvie has announced that it will cease the development of this drug.
- 28 Aug 2017 Planned End Date changed from 21 Apr 2018 to 16 Aug 2018.
- 28 Aug 2017 Planned primary completion date changed from 21 Apr 2018 to 16 Aug 2018.